Sign inJoin waitlistJoin the waitlist

Anna Halpern

Clinical Director for Leukemia and Myeloid Malignancies, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · ·

History

Fred Hutch · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Washington-Seattle Campus
2012–2015
Internal Medicine
University of Chicago Medical Center
2009–2012
Warren Alpert Medical School of Brown University
2005–2009

Research

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Journal of Clinical Oncology · 2016 · 372 citations
Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
Leukemia · 2016 · 178 citations
Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit
JAMA Oncology · 2017 · First of 4 authors · 68 citations

Roland Walter
46 papers
EE
Elihu Estey
31 papers
Mary-Elizabeth Percival
31 papers
PH
Paul Hendrie
23 papers
Pamela Becker
18 papers
Bart Scott
15 papers
Ryan Cassaday
14 papers
JA
Jacob Appelbaum
12 papers
Vivian Oehler
11 papers
SB
Sarah Buckley
8 papers · 2 as a fellow
EH
Emily Huebner
7 papers · 2 as a resident
AS
Andrei Shustov
6 papers

Clinical trials

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Principal investigator · Recruiting · Phase 2
University of Washington
2026–2028
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Principal investigator · Recruiting
University of Washington
2025–2027
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Principal investigator · Recruiting · Phase 2
University of Washington
2020–2027
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
Principal investigator · Completed · Phase 2
University of Washington
2016–2021